GPR78 promotes lung cancer cell migration and metastasis by activation of Gαq-Rho GTPase pathway

@article{Dong2016GPR78PL,
  title={GPR78 promotes lung cancer cell migration and metastasis by activation of G$\alpha$q-Rho GTPase pathway},
  author={Dan-dan Dong and Hui Zhou and Gao Li},
  journal={BMB Reports},
  year={2016},
  volume={49},
  pages={623 - 628}
}
GPR78 is an orphan G-protein coupled receptor (GPCR) that is predominantly expressed in human brain tissues. Currently, the function of GPR78 is unknown. This study revealed that GPR78 was expressed in lung cancer cells and functioned as a novel regulator of lung cancer cell migration and metastasis. We found that knockdown of GPR78 in lung cancer cells suppressed cell migration. Moreover, GPR78 modulated the formation of actin stress fibers in A549 cells, in a RhoA- and Rac1-dependent manner… 

Figures from this paper

The P2Y6 receptor signals through Gαq/Ca2+/PKCα and Gα13/ROCK pathways to drive the formation of membrane protrusions and dictate cell migration
TLDR
Results support the idea that the P2Y6 receptor represents a target of interest to modulate cell migration and revealed an intricate dialogue between two Gα‐protein signaling pathways.
MiR-188-3p/GPR26 modulation functions as a potential regulator in manipulating glioma cell properties
TLDR
Evidence for the cancer-promoting effect of miR-188-3p in GBM cells is provided and it is demonstrated that GPR26 was directly targeted by miR+3p, which might contribute to the therapeutic therapy of GBM.
miR-936 Suppresses Cell Proliferation, Invasion, and Drug Resistance of Laryngeal Squamous Cell Carcinoma and Targets GPR78
TLDR
It is testified that miR-936 was substantially downregulated in LSCC tissues compared with adjacent normal tissues and could inhibit proliferation, migration and invasion, and improve the sensitivity to doxorubicin and cisplatin of LSCC cells.
Opioids trigger breast cancer metastasis through E-Cadherin downregulation and STAT3 activation promoting epithelial-mesenchymal transition
TLDR
It is concluded that opioids trigger metastasis through oncogenic JAK1/2-STAT3 signaling and E-Cadherin downregulation are triggered by opioid-ligated DORs, promoting metastasis.
Endogenous Anti-Cancer Candidates in GPCR, ER Stress, and EMT
TLDR
There are a few proteins among these groups which impede deleterious effects by orchestrating the pro-apoptotic phenomenon and paving a therapeutic pathway and the present review exposes and discusses such critical mechanisms.
Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9
TLDR
It is reported that GRP significantly enhanced the proliferation and migration of rat VSMCs and upregulation of MMP-2/9 via STAT3 activation.
The tRNA-Derived Fragment tRF-24-V29K9UV3IU Functions as a miRNA-like RNA to Prevent Gastric Cancer Progression by Inhibiting GPR78 Expression
TLDR
It is suggested that the tRF-24-V29K9UV3IU/GPR78 axis serves as a potential therapeutic target in GC and functions as a miRNA-like fragment to suppress GPR78 expression and thus inhibit GC progression.
In silico structure prediction, molecular docking and dynamic simulation studies on G Protein-Coupled Receptor 116: a novel insight into breast cancer therapy
TLDR
The theoretical confirmatory structural properties changes support to prove selective crucial amino acids play the significant role in ligand binding in G Protein-Coupled Receptor 116 could be the best molecular target for breast cancer drug discovery.
The Good among the Bad and the Ugly: The Unsung Heroes in ER Stress, GPCR and EMT
TLDR
There are a few proteins among these groups which impede deleterious effects by orchestrating the pro-apoptotic phenomenon and paving a therapeutic pathway.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Gαq-p63RhoGEF-Rho GTPase pathway.
TLDR
Findings show that GPR 116 is crucial for the metastasis of breast cancer and support GPR116 as a potential prognostic marker and drug target against metastatic human breast cancer.
Orphan G Protein-coupled Receptor GPR56 Regulates Neural Progenitor Cell Migration via a Gα12/13 and Rho Pathway*
TLDR
Results indicate that GPR56 participates in the regulation of NPC movement through the Gα12/13 and Rho signaling pathway, suggesting its important role in the development of the central nervous system.
Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells
TLDR
It is reported that human GPR56 undergoes GPS (GPCR proteolytic site)-mediated protein cleavage to generate its extracellular domain as an N-terminal fragment (GPR56-N), and it is shown that GPR 56-N is highly glycosylated with N-linked carbohydrate chains.
Gα12/13 signaling promotes cervical cancer invasion through the RhoA/ROCK-JNK signaling axis.
GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion
TLDR
The results indicate that the extracellular domain may compete for unidentified ligand(s), and block the normal function of GPR56 in cell attachment, and serve as an adhesion GPCR and is involved in adhesion signaling.
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model
TLDR
An autonomous effect of CD97 on thyroid cancer progression is shown and supports the investigation of this GPCR as a therapeutic target for these cancers.
HAb18G/CD147 promotes cell motility by regulating annexin II‐activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells
TLDR
The interaction of HAb18G/CD147 with annexin II is involved in the interconversion between mesenchymal and amoeboid movement of hepatocellular carcinoma cells.
mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
TLDR
It is found that increased expression of mTOR, Raptor, and Rictor mRNA was noted with advanced stages of CRC, suggesting that mTOR signaling may be associated with CRC progression and metastasis, and provides the rationale for including mTOR kinase inhibitors, which inhibit both mTORC1 and m TORC2, as part of the therapeutic regimen for CRC patients.
...
...